Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination

Bone Marrow Transplantation

Volumn 21, Issue 8, 1998, Pages 747-749

  Kelemen, E ^a   Masszi, T ^b   Remenyi P ^b   Barta, A ^a   Paloczi K ^a  

^a National Institute of Haematology and Immunology Budapest   (Hungary)

^b Szent Laszlo Hospital   (Hungary)

Author keywords

Allogeneic BMT; Chronic myeloid leukemia; Dibromomannitol containing non myeloablative preconditioning; Identical; Transplant related complications

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; METHOTREXATE; MITOBRONITOL;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMORRHAGIC CYSTITIS; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER VENOOCCLUSIVE DISEASE; MUCOSA INFLAMMATION; NURSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; SEPSIS; WORKLOAD;

EID: 0031918108     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701167     Document Type: Article

References (11)

1. Kelemen E, Jakab K, Váradi G et al. Non-supralethal mitobronitol/cytarabine/cyclophosphamide conditioning without irradiation before bone marrow transplantation for accelerated chronic granulocytic leukemia: apparent absence of acute graft-versus-host disease. Leukemia 1993; 7: 939-945.
2. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukaemia: the influence of plasma busulphan levels on the outcome of transplantation. Blood 1997; 89: 3056-3060.
3. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
4. Rowlings PA. 1996 summary slides show current use and outcome of blood and marrow transplantation. ABMTR Newsletter 1996; 3: 6-12.
5. van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukaemia in chronic phase. Bone Marrow Transplant 1997; 20: 553-560.
6. Savage DG, Szydlo RM, Chase A et al. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997; 99: 30-35.
7. Deisseroth AB, Kantarjian H, Andreeff M et al. Chronic leukemias. In De Vita V Jr, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology, 5th edn. Lippincott-Raven, Philadelphia, USA, 1997, pp 2334.
8. Barta A, Bátai Á, Sipos A et al. Low frequency of transplant-related complications using a radiation-free conditioning regimen in BMT of CML patients. Bone Marrow Transplant 1997; 19 (Suppl. 1): 128 (Abstr.).
9. Szebeni J, Barna K, Uher F et al. Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning. Leukemia 1997; 11: 1769-1774.
10. Apperley JF, Hermans J, van Biezen A, Gratwohl A. Risk assessment for allogeneic transplantation in chronic myeloid leukaemia. Bone Marrow Transplant 1997; 19 (Suppl. 1): 578 (Abstr.).
11. Kolb HJ, Schattenberg A, Goldman JA et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow-grafted patients. Blood 1995; 86: 2041-2045.